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We previously reported that BMRF-2, an Epstein–Barr virus (EBV) glycoprotein, binds to β1 family integrins and is important for EBV
infection of polarized oral epithelial cells. To further study the functions of BMRF-2, we constructed a recombinant EBV that lacks BMRF-2
expression by homologous recombination in B95-8 cells. We found that lack of BMRF-2 resulted in about 50% reduction of EBV attachment to
oral epithelial cells, but not to B lymphocytes, suggesting that BMRF-2 is critical for EBV infection in oral epithelial cells, but not in B
lymphocytes. In polarized oral epithelial cells, infection rate of the recombinant EBV virus was about 4- to 8-fold lower than the wild-type B95-8
virus. Cell adhesion assays using the BMRF-2 RGD peptide and its RGE and AAA mutants showed that the RGD motif is critical for BMRF-2
binding to integrins. These data are consistent with our previous observation that interactions between EBV BMRF-2 and integrins are critical for
infection of oral epithelial cells with EBV.
© 2007 Elsevier Inc. All rights reserved.Keywords: Epstein–Barr virus; BMRF-2; Integrin; Virion attachment; Oral epithelial cellsIntroduction
Epstein–Barr virus (EBV) is a human herpesvirus that
infects about 90% of the human population and it is associated
with lymphoid and epithelial neoplasia (Kieff and Rickinson A,
2001). EBV mainly infects B lymphocytes and epithelial cells;
however, accumulating evidence indicates that it also may
infect monocytes, macrophages, dendritic cells, and T cells
(Guerreiro-Cacais et al., 2004; Kashiwagi et al., 2007; Knol
et al., 2005; Masy et al., 2002; Savard et al., 2000; Schlitt et al.,
2005; Shimakage et al., 1999; Tugizov et al., 2007).
Initiation of EBV infection requires attachment of virions to
the host cell, followed by fusion of virus and cell membranes and
the release of viral capsids into the cytoplasm (Hutt-Fletcher,
2007; Spear and Longnecker, 2003). It is well known that in B
lymphocytes, EBV glycoprotein gp350/220 plays an important⁎ Corresponding author. Department of Medicine, University of California,
San Francisco, Box 0654 San Francisco, CA 94143-0654, USA. Fax: +1 415
476 9364.
E-mail address: sharof.tugizov@ucsf.edu (S.M. Tugizov).
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doi:10.1016/j.virol.2007.09.012role in virus attachment by binding to cell surface receptor
CD21. After attachment, fusion of the virus–cell membrane is
triggered by interactions of HLA class II molecules with EBV
glycoprotein gp42, which forms a complex with gHgL (Li et al.,
1997, 1995). EBV gB also is known to be important in the virus–
B lymphocyte cell membrane fusion (Haan et al., 2001).
However, the mechanisms involved in EBV attachment to and
entry into epithelial cells are less clear. Neither gp350/220 nor
gp42 is required for EBV infection of epithelial cells, in contrast
to gHgL and gB, which are essential (Hutt-Fletcher, 2007; Spear,
1993): gHgL is critical to virus attachment (Molesworth et al.,
2000), and its coordinated functions with gB mediate fusion of
the virus–cell membrane in epithelial cells (Borza et al., 2004;
McShane and Longnecker, 2004; Omerovic et al., 2005).
Interactions between BMRF-2 and the β1 family of integrins
also are critical for infection of polarized oropharyngeal
epithelial cells with EBV (Tugizov et al., 2003).
BMRF-2 is an EBV glycoprotein with highly hydrophobic,
multi-span transmembrane domains and an arginine–glycine–
aspartate (RGD) motif in its major extracellular domain (Tugizov
et al., 2003; Xiao et al., 2007). The RGD motif is present in
extracellular matrix proteins, which bind to integrins and play a
431J. Xiao et al. / Virology 370 (2008) 430–442vital role in cell adhesion and cell-to-cell communication (Friedl
et al., 1998a; Giancotti and Ruoslahti, 1999; Gilcrease, 2007;
Ruoslahti, 1996). Viral proteins containing the RGD motif may
serve as ligands for integrins leading to attachment of virions to
host cells (Triantafilou et al., 2001). BMRF-2 is highly expressed
in the upper differentiated layer of oral hairy leukoplakia (HL)
lesions, where the virus actively replicates (Lagenaur and
Palefsky, 1999; Palefsky et al., 1997; Xiao et al., 2007). The
promoter of BMRF-2 is up-regulated by mechanisms known to
induce differentiation of epithelial cells (Lagenaur and Palefsky,
1999). BMRF-2 is associated with the viral envelope and binds to
α3, α5, αv, and β1 integrins through its RGD domain (Tugizov
et al., 2003; Xiao et al., 2007). Antibodies to β1 family integrins
and to the BMRF-2 protein significantly block infection of EBV
in polarized oral epithelial cells, which express high levels of
integrins on the basolateral membranes (Tugizov et al., 2003).
Treatment with the same antibodies does not affect EBV infection
inB lymphocytes, which express lower levels of integrins (Tugizov
et al., 2003). These findings indicate that interactions between
EBV BMRF-2 and β1 family integrins may be critical for efficient
EBV infection in oral epithelial cells but not B lymphocytes.Fig. 1. Construction of the recombinant EBV virus, EBV/ΔBMRF-2. (A) Schematic view
represent the locations of the nucleotides in the EBVB95-8 genome (AccessionNumberNC
B3′, for NK) on genomic DNA fromB95-8 and B27-BMRF-2low cells. (C) Results of Sou
B95-8 and B27-BMRF-2low cells digested with restriction enzyme Eco RI which gives a 6
(recombinant) band for the NK probe. A5′, A3′, B5′, and B3′ represents primers EB8041Binding of viral proteins with cell surface integrins plays an
important role in initiating virus infection and dissemination
(Triantafilou et al., 2001). Integrins are a large family of hertero-
dimeric cell surface receptors consisting of multiple α and β
subunits, most of which bind extracellular matrix proteins through
their RGD motif (Friedl et al., 1998a; Giancotti and Ruoslahti,
1999; Gilcrease, 2007; Ruoslahti, 1996). Binding of viral proteins
to integrins is mostly RGD-dependent, as seen in human herpes-
virus 8 (α3β1) (Akula et al., 2002), EBV (α3, α5, αv, and β1)
(Tugizov et al., 2003), hantavirus (β3) (Gavrilovskaya et al.,
1999), rotavirus (α2β1) (Ciarlet et al., 2002), foot-and-mouth
disease virus (αvβ3) (Jackson et al., 1997),West Nile virus (αvβ3)
(Chu and Ng, 2004), echovirus (αvβ6) (Triantafilou and
Triantafilou, 2001) and coxsackie virus (αvβ6) (Williams et al.,
2004). However, interactions between viral glycoproteins and
integrins also can be RGD-independent, as shown in human
cytomegalovirus (HCMV), which attaches to α2β1 and αvβ3
integrins through gBand gH, respectively (Feire et al., 2004;Wang
et al., 2005). Upon binding to viral attachment proteins, integrins
may activate downstream signaling pathways leading to internal-
ization of the virus into the host cell (Krishnan et al., 2006;of the EBV genome and the shuttle vector for homologous recombination. Numbers
_001345). (B) Results of PCRusing primer sets A (A5′+A3′, for GFP) andB (B5′+
thern blot analysis using a BMRF-2 probe and an NK probe and genomic DNA from
.4 kb (WT) band and a 1.6 kb (recombinant) band for the BMRF-2 probe, and a 3 kb
2-31, GFP2089-2112, Nk1606-27, and EB82630-50, respectively.
432 J. Xiao et al. / Virology 370 (2008) 430–442Medina-Kauwe, 2003; Pietiainen et al., 2004; Sharma-Walia et al.,
2004; Wang et al., 2005).
In the present study, we further examined the role of BMRF-2 in
the infection of oral epithelial cells using a recombinant EBV that
lacks expression of BMRF-2.We found that lack of BMRF-2 in the
virion envelope leads to a substantial reduction of EBVattachment
and infection in oral epithelial cells, but not B lymphocytes.Fig. 2. Viral gene expression in B95-8 and B27-BMRF-2low cells. (A) The ratio of recom
quantitated using the BZLF-1 probe and recombinant virions were quantitated by the N
(B) RT–PCR detection of BMRF-1, BMRF-2, and BZLF-1 expression in B95-8 and B2
with or without PMA (30 ng/ml) for 5 days before total RNAwas extracted. 5 μl of
expression of both BMRF-2 and BZLF-1 in the same PCR reaction. The bottom panel sh
gp350/220, andBMRF-1 expression inB95-8 andB27-BMRF-2low cells. For BMRF-2 a
well of a 7M urea SDS–PAGE gel. BMRF-1 was detected using total cell lysates sepa
β-actin expression in noninduced B95-8 and B27-BMRF-2low cells. 10 μg of total cell ly
of pixels of the protein bands shown in panels C and D was measured by the NIH Imag
background values were subtracted from each protein band. (E) Cell surface detection
BMRF-2 serum.Histograms are labeled as the following: 1, normal rat serum staining of
2, B27-BMRF-2low cells reacted with rat anti-BMRF-2 serum; 3, B95-8 cells reacted wResults
Selection of a marmoset B lymphoblastoid cell line producing
recombinant EBV that lacks BMRF-2 expression
To construct the recombinant virus, EBV/ΔBMRF-2, B95-
8 cells were transfected with linearized shuttle vector DNA, pB-binant EBV toWTEBVin B27-BMRF-2low cells. Total EBV copy numbers were
K probe, numbers represent the percentages of total viral genome copy numbers.
7-BMRF-2low cells. 5×106 each of B95-8 and B27-BMRF-2low cells were treated
cDNA (out of 20 μl reaction) were used as PCR templates. The top panel shows
ows expression of theBMRF-1 gene. (C)Western blot analysis showing BMRF-2,
nd gp350 detection, 10μg of themembrane fraction proteinswere loaded onto each
rated on a NuPage 10%Bis–Tris gel. (D)Western blot detection of EBNA-1 and
sates were loaded onto each well in a NuPage 10%Bis–Tris gel. The mean density
e software, and the results of each gel are shown as a bar graph under each blot and
of BMRF-2 by flow cytometry in B95-8 and B27-BMRF-2low cells using rat anti-
these two cell lines (since the histogramswere almost identical, only one is shown);
ith rat anti-BMRF-2 serum. MN, mean fluorescence intensity.
Fig. 3. Virion release from B95-8 and B27-BMRF-2low cells. (A) Analysis of
released virions by quantitative real-time PCR. B95-8 and B27-BMRF-2low cells
were cultured in the presence of PMA and butyric acid for 5 days, and total genomic
DNA from cells ormediawas extracted separately. EBVgenome copy numberswere
quantitated by real-time PCR and number of released virions in medium from B95-
8 or B27-BMRF-2low cells were shown as % of total, which equals to the number of
virions from cells and medium together. Error bars represent standard deviations
(SDs) of three independent experiments. (B)Western blot analysis of double gradient
purified virions from B95-8 or B27-BMRF-2low cells using rat anti-BMRF-2 serum.
10μgof total viral proteinswere loaded onto eachwell of a 7MureaSDS–PAGEgel.
433J. Xiao et al. / Virology 370 (2008) 430–442GFP-NK (Fig. 1A), and neomycin-resistant cells were selected
by G418. Because the poly-A signal for BMRF-1 mRNA is
located within the BMRF-2 coding sequence, it is possible that
knockout of the BMRF-2 gene also prevents BMRF-1 expres-
sion in EBV/ΔBMRF-2. To prevent this disruption, HSV-TK
poly-Awas inserted in the 3′ untranslated sequence of BMRF-1
just downstream of the upstream homologous sequence to pro-
vide a poly-A signal for BMRF-1 expression (Fig. 1A). We used
a PCR method to screen neo-resistant clones that carried EBV/
ΔBMRF-2 using primer sets A and B (Fig. 1A). Because each
pair of primers consisted of one primer specific for the sequence
present and one for the part of EBV genome not present in the
shuttle vector, only recombinant viruses should be tested posi-
tive by PCR. Twenty-two of the 150 neomycin-resistant clones
tested positive by both pairs of primers for recombination (data
not shown). One of the positive clones, designated B27-BMRF-
2low, showed the strongest PCR signal for both primer sets
(Fig. 1B) and was chosen for further expansion and Southern
blot analysis. Fig. 1C shows the results of a Southern blot
test using both a BMRF-2 probe and an NK probe. The BMRF-2
probe detected WT EBV DNA as a 6.4 kb fragment and recom-
binant DNA as a 1.6 kb fragment, as expected. Only the
WT EBV DNAwas detected in B95-8 cells. Although both the
WT and the recombinant EBV genome were detected in B27-
BMRF-2low using the BMRF-2 probe, the lower band (recom-
binant) was much stronger than the upper band (WT), indicating
that the cells contained mainly the recombinant EBV/ΔBMRF-
2. The NK probe detects only EBV/ΔBMRF-2 DNA, whichwas
expected in B27-BMRF-2low but not in B95-8 (Fig. 1C).
To obtain cell lines producing only the recombinant EBV/
ΔBMRF-2, we attempted to rescue the recombinant in two EBV-
negative B lymphoblastoid cell lines, Akata 4E-3 and BJAB cells.
At least 10 rescue experiments were performed in each cell line
using 1–2×106 to 107 cells infectedwith virions at 2–10MOI, and
more than 3000 neo-resistant colonies were obtained initially.
However, only a few colonies could be expanded and tested for the
presence of the EBV/ΔBMRF-2 recombinant. Unfortunately, none
of the surviving neo-resistant clones contained any EBV/ΔBMRF-
2 genome, as it was either lost or had reverted to WT EBV.
Characterization of the B27-BMRF-2low virus
In the absence of pure recombinant EBV/ΔBMRF-2 virus, we
characterized the B27-BMRF-2low cell line for the present study.
To determine the ratio of WT EBVover EBV/ΔBMRF-2 in this
cell line, we performed quantitative real-time PCRusing aBZLF-1
probe for total EBV genome and an NK probe for the EBV/
ΔBMRF-2 genome. We found that about 85% of genomic viral
DNA copies in both intracellular and released virions of the B27-
BMRF-2low cells were recombinant EBV DNA (Fig. 2A). To
examine the stability of recombination in B27-BMRF-2low cells,
we tested the ratio of recombinant/WT EBV in this cell line at
different passages and found that the ratio is stable during the
expansion of the B27-BMRF-2low cell line over more than 30
passages under G418 selection.
To compare expression of BMRF-2, BMRF-1, EBNA-1,
BZLF-1, and gp350/220 in B95-8 and B27-BMRF-2low cells, weperformed RT–PCR, Western blot and flow cytometry assays.
Small amounts ofBMRF-2RNAwere detected byRT–PCRunder
non-inducing conditions in B95-8 cells, but not in B27-BMRF-
2low cells (Fig. 2B). After PMA induction, expression of all three
genes – BMRF-2, BZLF1, and BMRF-1 – was greatly increased
in B95-8 cells. In B27-BMRF-2low cells, however, comparable
levels of expression were found only for BZLF-1 and BMRF-1.
The amount of BMRF-2 RNA in B27-BMRF-2low cells was
substantially lower than that in B95-8 cells (Fig. 2B). These data
indicate that knockout of BMRF-2 did not affect expression of
BZLF-1 and BMRF-1, which are critical for EBV lytic infection.
Western blot analysis of BMRF-2 and gp350/220 in the
membrane fraction of PMA-induced B95-8 and B27-BMRF-2low
cells showed similar expression of gp350/220 in B95-8 and B27-
Fig. 4. Analysis of attachment of B95-8 and B27-BMRF-2low virus to oral epithelial and Akata 4E-3 B lymphocytes. (A) Detection of virus attachment by real-time
PCR. The B95-8 and B27-BMRF-2low viruses were added independently to HSC-3sort, Detroitsort, and Akata 4E-3 cells and incubated at 4 °C for 1 h. Cells were
washed, and genomic DNA extracted and bound virions were examined by real-time PCR. (B) Evaluation of virus binding by flow cytometry assay. HSC-3sort and
Akata 4E-3 cells were incubated with B95-8 or B27-BMRF-2low viruses for 1 h at 4 °C and washed, and attached virions were detected using mouse monoclonal anti-
gp250/350 (left panel), anti-gp110 (anti-gB, middle panel), or anti-gH (right panel). The amount of virions bound to the cell surface was examined by flow cytometry
and the results are shown as histograms labeled as follows: 1, cells incubated with the B95-8 virus and reacted with mouse IgG1; 2 and 3, cells incubated with the B27-
BMRF-2low and the B95-8 virus, respectively, and reacted with one of the above monoclonal antibodies. MN, mean fluorescence intensity.
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B27-BMRF-2low cells (Fig. 2C). Under PMA induction, we
found the rate of lytic induction is similar in both B95-8 and B27-
BMRF-2low cells (data not shown). Analysis of total cell extracts
showed that BMRF-1 expression was similar in both B95-
8 and B27-BMRF-2low cells (Fig. 2C). These data indicate
that expression of two lytic proteins of EBV (gp350/220 and
BMRF-1) was not affected by knockout of BMRF-2. To
determine whether knockout of BMRF-2 affected the expression
of latent EBV genes, such as EBNA-1, we examined the protein
expression of EBNA-1 in latent B95-8 and B27-BMRF-2low cells
byWestern blotting. Under noninduced conditions, the amount of
EBNA-1 protein was also similar in both cell lines (Fig. 2D),
suggesting that EBNA-1 expression also was not affected by
disruption of the BMRF-2 gene.To determine surface expression of the BMRF-2 protein in
B95-8 and B27-BMRF-2low cells, PMA-induced cells were
analyzed by flow cytometry assay using rat anti-BMRF-2
serum. We observed a substantial reduction of BMRF-2 on
B27-BMRF-2low cells compared with B95-8 cells, with a mean
fluorescence intensity of 20 and 270, respectively (Fig. 2E).
This result correlated with Western blot analysis, which showed
a low level of BMRF-2 protein in the membrane fraction of
B27-BMRF-2low cells (Fig. 2C).
BMRF-2 may not be required for virion assembly and release
To determine whether knockout of BMRF-2 affects assembly
of viral particles, we examined the morphology of virions in
PMA-induced B95-8 and B27-BMRF-2low cells under electron
435J. Xiao et al. / Virology 370 (2008) 430–442microscopy, and we found no differences in the morphology of
virions from these two cell lines (data not shown). To investigate
whether BMRF-2 plays a role in the release of progeny virions,
the B85-8 and B27-BMRF-2low cells were grown under the
same conditions and induced by PMA and butyric acid for
5 days. Cells and media were then collected separately and
examined for copies of the EBV genome by quantitative real-
time PCR. We found no difference in the rate of release between
B95-8 and B27-BMRF-2low viruses, indicating that virions from
B27-BMRF-2low cells were released as efficiently as from B95-
8 cells (Fig. 3A). To determine whether BMRF-2 was present in
released WT and B27-BMRF-2low virions, double gradient-
purified WT and B27-BMRF-2low viruses were examined for
BMRF-2 and gp350/220 protein expression by Western blot
assays (Fig. 3B). Analysis of BMRF-2 in released virions from
B95-8 cells showed the presence of multiple smeary, but strong
bands, which is typical for this protein due to its highly
hydrophobic nature (Xiao et al., 2007). In contrast, virions from
B27-BMRF-2low cells showed only weak bands, which repre-
sent BMRF-2 expressed from the WT virus that was present
among the BMRF-2 knockout virus population (about 85%).
Quantitative analysis of BMRF-2 protein bands showed thatFig. 5. Infection of polarized oral epithelial cells with B95-8 or B27-BMRF-2low viru
from their basolateral membranes at 100 MOI. At 5 days after infection, cells were
stained in blue. (B) Polarized HSC-3sort, Detroitsort and OCO cells were infected with
cell. Cells were fixed at 5 days post-infection and immunostained with gp350/220 ant
of gp350/220-positive cells from individual filer membranes. Error bars show SD (nmean pixels were 158 and 29 for B95-8 and B27-BMRF-2low
virions, respectively (Fig. 3B). Analysis of the same samples for
gp350/220 showed an equal amount in both viruses with a mean
pixel value of 160 each. These data clearly demonstrate that the
amount of BMRF-2 protein in B27-BMRF-2low virions was
about 80% less than the amount in B95-8 virions and that lack of
BMRF-2 did not affect the egress of progeny virions.
BMRF-2 is required for EBV attachment to epithelial cells but
not to B lymphocytes
In the above experiments, we confirmed that B27-BMRF-2low
cells produce predominantly virions containing the EBV/
ΔBMRF-2 genome (about 85%), and only about 15% of WT
viral genome as demonstrated by real-time PCR quantification of
WT and EBV/ΔBMRF-2 genome copy numbers (Fig. 2A). Also,
Western blot analysis of purified B27-BMRF-2low and wild-type
B95-8 virions showed that B27-BMRF-2low virions contain sub-
stantially lower amount of BMRF-2 protein than in B95-8 virus
(Fig. 3B). Therefore, we used B27-BMRF-2low virions to deter-
mine whether BMRF-2 is essential for EBV attachment to oral
epithelial and B lymphocytes. For attachment assays, HSC-3sort,s. (A) Polarized OCO cells were infected with B95-8 or B27-BMRF-2low virus
fixed and stained with mouse anti-gp350/220 antibody (red). Cell nuclei were
B95-8 or B27-BMRF-2low virus from their basolateral membranes at 100 MOI/
ibodies; positive cells were counted. Numbers shown are the average percentage
=3).
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B27-BMRF-2low virions at 5 MOI/cell and 25MOI/cell on ice for
60 min, and the amounts of attached virions were quantitated by
real-time DNA PCR. We found that binding of B27-BMRF-2low
virions to HSC-3sort and Detroitsort cells was about 50% less than
that of B85-8 virus (Fig. 4A). However, the amount of virions
attached to EBV-negative Akata 4E-3 cells was similar for both
B95-8 and B27-BMRF-2low virus (Fig. 4A).
To confirm the results of real-time PCR assays, we examined
the attachment of B95-8 and B27-BMRF-2low viruses to HSC-
3sort and Akata 4E-3 cells by flow cytometry using anti-gp350/
220, anti-gp110 (gB), and anti-gH antibodies. We found a
significant reduction in the binding of B27-BMRF-2low virus to
HSC-3sort cells, compared with B95-8 virus, but a similar rate at
which both viruses bind to the Akata 4E-3 cells (Fig. 4B). These
data clearly indicate that the binding of the B27-BMRF-2lowFig. 6. Adhesion of HSC-3sort cells to BMRF-2 RGD-coated plates. (A) Purification o
from the GST-BMRF-2 RGD fusion protein and purified by Centricon-10. 10 μg of G
peptide (right lane) were separated on an SDS–PAGE gel and stained by simple blue
with the BMRF-2 RGD peptide or fibronectin at different concentrations. (C) Adhe
EBV-positive serum, or rat anti-BMRF-2 serum were added to a Maxisorp 96-well pl
the plate; anti-β1 and anti-αv antibodies were incubated with HSC-3sort cells on ice fo
of HSC-3sort cells to the wells of a Maxisorp 96-well plate coated with PBS, BMRF
adhesion was examined bymeasuring attached cells after crystal violet staining using a
three independent experiments. (For interpretation of the references to colour in thisvirus to oral epithelial cells is substantially reduced, but did not
change in B lymphocytes. In addition, these data show that the
amounts of glycoproteins gp350/220, gB and gH are also
normal in B27-BMRF-2low virus.
BMRF-2 is important for EBV infection of polarized oral
epithelial cells
Our previous work showed that EBV infection in polarized
oral epithelial cells occurs from their basolateral membranes
and that BMRF-2 may play a critical role in this infection
(Tugizov et al., 2003; Xiao et al., 2007). To confirm this
observation, we examined the infectivity of both B95-8 and
B27-BMRF-2low viruses in polarized HSC-3sort, Detroitsort, and
OCO cells. Polarized oral epithelial cells were infected with
either B95-8 virus or B27-BMRF-2low virus at 100 MOI fromf the BMRF-2 RGD peptide: BMRF-2 RGD fragment was cleaved by thrombin
ST-BMRF-2 RGD fusion protein (left lane) and 1 μg of purified BMRF-2 RGD
(Invitrogen). (B) Adhesion of HSC-3sort cells to a Maxisorp 96-well plate coated
sion of HSC-3sort cells was blocked by different antibodies: EBV-negative sera,
ate coated with the BMRF-2 RGD peptide before HSC-3sort cells were applied to
r 60 min before they were added to the BMRF-2 RGD-coated plate. (D) Adhesion
-2 RGD peptide, BMRF-2 RGE peptide, or BMRF-2 AAA peptide. (B–D) Cell
n ELISA-plate reader with a 595 nm absorbance filter. Error bars represent SD of
figure legend, the reader is referred to the web version of this article.)
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infected cells were detected by immunofluorescence staining
using an antibody specific for gp350/220. Immunostaining of
gp350/220 in polarized HSC-3sort, Detroitsort (data not shown),
and OCO cells (Fig. 5A) showed localization of this protein to
the membrane and cytoplasm, as observed in our earlier work
(Tugizov et al., 2003; Xiao et al., 2007). Quantitative analysis
of infected cells showed that infection rates of the B95-8 virus
were 4- to 8-fold higher than those of the B27-BMRF-2low
virus in polarized oral epithelial cells (Fig. 5B). The gp350/
220-positive cells were 4.1%, 5.1%, and 13.5% in HSC-3sort,
Detroitsort, and OCO cells, respectively, after B95-8 virus
infection, but only 0.5%, 0.8%, and 3.8%, respectively, after
B27-BMRF-2low virus infection. These data show that B27-
BMRF-2low virus has substantially lower efficiency in
infecting polarized oral epithelial cells from their basolateral
membranes.
The extracellular RGD motif of BMRF-2 mediates HSC-3sort
cell adhesion
The above experiments showed that attachment and entry of
B27-BMRF-2low virus into oropharyngeal epithelial cells was
significantly impaired, indicating that BMRF-2 is critical in this
process. Our earlier findings showed that antibodies to BMRF-
2, and β1 and/or α5β1 integrins inhibit EBVattachment to oral
epithelial cells and that BMRF-2 RGD binds to β1 and αv
integrins (Tugizov et al., 2003; Xiao et al., 2007), suggesting
that the extracellular domain containing the RGD motif may
play a key role in BMRF-2's function. To determine the role of
the BMRF-2 RGD motif in attachment of the virus to oral
epithelial cells, we examined adhesion of HSC-3sort cells to 96-
well plates coated with BMRF-2 RGD peptide or its mutant
derivatives.
The purified BMRF-2 RGD fragment consisting of 48 amino
acids (Fig. 6A) was used to coat 96-well plates. These ex-
periments showed that HSC-3sort cells attached to the BMRF-2
RGD peptide-coated plates in a dose-dependent manner
(Fig. 6B), the efficiency of which was similar to fibronectin at
higher concentrations (Fig. 6B). Binding of HSC-3sort cells to
BMRF-2 RGD-coated plates was specifically blocked by rat
anti-sera to BMRF-2 and β1 integrin, and mouse monoclonal
anti-αv antibodies, indicating that adhesion is due to specific
interaction between this peptide and integrins, such as β1 and
αv. Two EBV-positive human sera previously shown to bind to
BMRF-2 on the surface of 293 cells transfected with BMRF-2
(Xiao et al., 2007) also significantly reduced adhesion of HSC-
3sort cells to BMRF-2 RGD-coated plates (Fig. 6C). To confirm
that interactions between BMRF-2 and integrins were RGD
dependent, we tested the efficiency of HSC-3sort cell adhesion
to mutant BMRF-2 RGD peptides, BMRF-2 RGE, and BMRF-
2 AAA. Substitution of RGD with RGE significantly reduced
HSC-3sort cell adhesion, and replacement of the RGD sequence
with AAA eliminated the ability of the RGD peptide to mediate
adhesion of HSC-3sort cells to the plates (Fig. 6D). These results
demonstrate that the RGD sequence is critical for BMRF-2
binding to integrins.Discussion
Our previous work showed that BMRF-2 binds to β1 and
αv family integrins through its RGD-containing extracellular
domain and that antibodies to BMRF-2, and β1 and/or α5β1
integrins reduce EBV attachment to polarized oral epithelial
cells, suggesting that the interaction of BMRF-2 with integrins
may be an important determinant for EBV infection in these
cells (Tugizov et al., 2003; Xiao et al., 2007). In the present
study, our goal was to further investigate the role of BMRF-2
in the infection of oral epithelial cells with EBV by a
constructing recombinant EBV that lacks BMRF-2 expression.
In homologous recombination experiments using B95-8 cells,
we selected the clonal cell line B27-BMRF-2low that produced
predominantly BMRF-2 knockout virus. However, we were
unable to rescue pure EBV recombinant that lacks BMRF-2.
We cannot explain the difficulties encountered in rescuing pure
BMRF-2 knockout EBV, as BMRF-2 has not been shown to be
an essential protein for EBV latency. It is also unlikely that
insertion of the GFP-NK cassette influences expression of
other genes essential for EBV replication or latency. By RT–
PCR and Western blot analyses, we showed that BMRF-1,
gp350/220, and BZLF-1 were expressed normally in B27-
BMRF-2low cells (Figs. 2B and C). Using Western blot
analysis, we found that the level of EBNA-1 expression in
B27-BMRF-2low cells was similar to that in B95-8 cells (Fig.
2D), indicating that knockout of BMRF-2 does not affect
expression of EBNA-1, a protein that is essential for
maintaining EBV latency (Leight and Sugden, 2000). A great
deal of our efforts have been put to use the EBV-bacterial
artificial chromosome system (kindly provided by Drs. K
Takada and T Kanda (Kanda et al., 2004) for constructing
BMRF-2 knockout EBV recombinants, but this approach also
has not been successful for us. Although it is not ideal to use a
mixture of WT and recombinant virus in the current study,
valuable information had been published by other investigators
using nonrescued EBV recombinants, which were also created
in B95-8 cells (Speck et al., 1999).
Detailed analysis of B27-BMRF-2low cells showed that
about 85% of the EBV virions from these cells contain the EBV/
ΔBMRF-2 genome (Fig. 2A) and the amount of the BMRF-2
protein is significantly lower in B27-BMRF-2low virus than in
B95-8 virus (Fig. 3B), and therefore this model was suitable to
study the function of BMRF-2. Virions lacking the BMRF-2
protein were released normally from B27-BMRF-2low cells
suggesting that BMRF-2 may not be critical for virus egress
although the BMRF-2 protein can be partially complemented by
the WT virus. Substantial reduction in attachment (about 50%)
of B27-BMRF-2low virus to oral HSC-3sort and Detroitsort
indicates that BMRF-2 was responsible for virion attachment to
the surface of oral epithelial cells. However its ability to attach
to and infect EBV-negative Akata 4E-3 cells is similar to that of
B95-8 virus (Fig. 4). These data suggest that BMRF-2 function
is restricted to oral epithelial cells, which express high levels of
β1 family integrins (Tugizov et al., 2003). This observation
confirms our previous finding that antibodies against BMRF-2,
β1 and/or α5β1 integrins reduced EBV infection in polarized
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2003).
Infection of polarized oral epithelial cells by B27-BMRF-
2low virus leads to significant reduction in infection (Fig. 5),
which was consistent with our previous findings that antibodies
to BMRF-2 and β1 family integrins also inhibit EBV infection
in polarized oral epithelial cells (Tugizov et al., 1995).
Proteomic analysis of purified EBV showed that the level of
BMRF-2 in the virion envelope is very low (Johannsen et al.,
2004). However, our data show that virions lacking BMRF-2
substantially lose their binding and infectious activity in oral
epithelial cells (Figs. 4 and 5), indicating that the presence of
BMRF-2 in the virion envelope is critical for EBVattachment to
and infection of these cells. Previously, we showed that full
separation of BMRF-2 in commonly used protein–gel systems
is not always feasible due to its highly hydrophobic nature,
which generates a multi-spanning glycoprotein with 10 poten-
tial transmembrane domains (Tugizov et al., 2003; Xiao et al.,
2007). Therefore, it may not be possible to determine the exact
amount of this protein in the virion envelope by standard gel-
separation systems.
We previously reported that BMRF-2 binds to integrins β1,
α3, α5, and αv through its RGD-containing extracellular do-
main fused to the GST protein (Tugizov et al., 2003; Xiao et al.,
2007). In this report, we show that the BMRF-2 RGD peptide
mediates adhesion of HSC-3sort cells in a dose-dependent man-
ner. The efficiency of BMRF-2 RGD-mediated cell adhesion
was comparable to cell adhesion to the fibronectin, which is the
main ligand for α5β1 integrin (Larsen et al., 2006; Takagi,
2004). BMRF-2 RGD-dependent cell adhesion was specifically
blocked by antibodies to BMRF-2, and β1 and αv integrins.
Substitution of the RGD sequence with RGE or AAA also
reduced or eliminated the ability of the BMRF-2 RGD peptide to
mediate adhesion of HSC-3sort cells (Fig. 6). These findings
clearly demonstrate that BMRF-2 is a virion attachment glyco-
protein that mediates binding of EBV to oral epithelial cells
through the interaction of its RGD-containing extracellular
domain with integrins.
Accumulating evidence indicates that binding of viral
proteins with integrins may establish initial virion attachment
to the surface of the host cell (Adam, 2001; Akula et al., 2002;
Jackson et al., 1997; Triantafilou and Triantafilou, 2001). The
well-known glycoproteins of human cytomegalovirus, gB and
gH, and human herpesvirus-8 gB bind cell surface integrins and
facilitate virion binding (Akula et al., 2002; Feire et al., 2004;
Wang et al., 2005). Recent work by May et al., (May et al.,
2005) showed that the BMRF-2 homologue of the gamma-
herpesvirus-68, ORF-58, also may function as an attachment
protein. Interestingly, the attachment function of ORF-58 is
mediated by its extracellular loop (between aa 163 and aa 200),
which is highly homologous with the extracellular loop of
BMRF-2. However, ORF-58 does not have the RGDmotif in its
extracellular domain, suggesting that ORF-58 binding to host
cells may be independent of integrins.
In summary, our results show that BMRF-2 serves as an
attachment protein for EBV in oral epithelial cells and therefore
may play an important role in early events of EBV infectionwithin the oropharyngeal mucosal epithelium. Moreover, our
data show that a minimal role for BMRF-2 in EBV infection of
B lymphocytes, suggesting that BMRF-2 may have specific
functions in the epithelium, as most β1 and αv integrins are
highly functional and generate multiple signaling events in
highly adhesive epithelial cells, in contrast to B lymphocytes
(Friedl et al., 1998a,b; Giancotti and Ruoslahti, 1999; Gilcrease,
2007; Larsen et al., 2006; Takagi, 2004; Yamada et al., 2003).
Further studies are needed to understand the downstream
signaling events initiated by BMRF-2-integrin interactions and
their role in the infection of oral epithelial cells with EBV.
Material and methods
Cell culture
The EBV-producing marmoset B lymphoblastoid cell line
B95-8 EBV-negative BJAB and Akata 4E-3 cells (a gift from
Dr. L Hutt-Fletcher at Louisiana State University, Health
Sciences Center, Shreveport, LA) were maintained in RPMI
1640 medium supplemented with 10% fetal calf serum and
antibiotics. Two EBV permissive cell lines, HSC-3sort tongue
and Detroitsort pharyngeal, and the HSC-3sort/BMRF-2 cell line
constitutively expressing BMRF-2 were previously established
in our laboratory (Tugizov et al., 2003; Xiao et al., 2007). The
cells were maintained in Dulbecco's modified Eagle's medium
(DMEM) containing 10% fetal bovine serum (FBS) (HyClone,
Logan, UT), 200 mM L-glutamine, 0.1 mg/ml streptomycin,
and 100 U/ml penicillin. Primary tongue keratinocyte (OCO)
cells were previously established from human tongue tissue
(University of California, San Francisco, Committee on Human
Research approval #RS00908) in our laboratory and were
grown in keratinocyte growth medium (Cambrix Bio Science,
Walkersville, MD) (Tugizov et al., 2003).
Construction of recombinant EBV that lacks expression of
BMRF-2
A recombinant virus, designated EBV/ΔBMRF-2, was
constructed by a homologous recombination method (Fig. 1).
To disrupt expression of the BMRF-2 gene, we used a PCR-
generated DNA fragment containing green fluorescence protein
(GFP) and neomycin/kanamycin (NK) resistance (aminoglyco-
side phosphotransferase) expression cassettes to replace 360
nucleotides (81361–81720) of the BMRF-2 open reading frame
(ORF) in EBV B95-8 strain (Accession Number NC_001345).
The GFP is driven by the HCMV immediate early promoter and
the NK protein is expressed under the SV40 promoter. After
recombination, the BMRF-2 protein was truncated after 81 amino
acids (81118–81361). The shuttle vector plasmid, designated pB-
GFP-NK, containing the upstream (EBV genome 80461–81360)
and downstream (EBV genome 81721–82515) homologous
sequences, the GFP expression cassette, and the neomycin resis-
tance expression cassette (Fig. 1) was constructed by PCR-
cloning using the following primers: (1) Primers for amplification
of the upstream homologous sequence: bmrf1-5, ggtgacactcaatcc-
ggatc; bmrf1-3bam, gtaggatccattcagcatgatggctggag. (2) Primers
439J. Xiao et al. / Virology 370 (2008) 430–442for amplification of the downstream homologous sequence:
bmrf2-dn5pst, tacctgcagattcggtggcatccctgaag; bmrf2-dn3gccg-
acttctggaacatttg. (3) Primers for amplification of the GFP-
expression cassette: cmv-p-gfp5, gtattaccgccatgcattag; cmv-p-
gfp3, aaccacaactagaatgcagtg. (4) Primers for amplification of
the NK resistance expression cassette: Nk-5, tcagttagggtgtg-
gaaagtc; Nk-3, caaacgacccaacaccgtgcg. The upstream and down-
stream homologous sequences were first cloned into psp72 by
PCR cloning. The HSV-thymidine kinase poly-adenylation signal
(HSV-TK-pA: sense strand, gatcaataaaaagacagaataaag; antisense
strand, gatcctttattctgtctttttatt) were then inserted into the BamH I
site at the 3′end of the upstream homologous sequence. The PCR
products of the GFP and NK expression cassettes were inserted
into the BamH I and Pst I sites, respectively, by blunt-ended
ligation after treating the vector and PCR products with T4 DNA
polymerase. For homologous recombination, the plasmid DNA of
pB-GFP-NK was linearized with restriction enzyme Pvu I. 20 μg
of the linearized DNA were transfected into 5×106 B95-8 cells
using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) according to
the manufacturer's protocol. 48 h after transfection, cells were
plated into 96-well plates with 104 cells per well in 200 μl of
selection medium (RPMI 1640 with 10% FBS and 800 μg/ml
G418), and half of the culture medium was replaced every 5 days
with fresh selection medium. Three weeks after transfection,
G418-resistant colonies were expanded and tested by PCR for
recombination. Two pairs of primers were used to test recombi-
nation between the shuttle vector and the EBV genome: Primer set
A (for GFP), A5′ (EB80412), 5′-gcttcctcgttgcagaagtg and A3′
(Gfp2089), 5′-tgttgttaacttgtttattgcagc; and primer set B (for NK),
B5′ (Nk1606), 5′-taactgacacacattccacagc and B3′ (EB82630), 5′-
tatcggatgcctcacgcgaag).
To rescue pure recombinant EBV/ΔBMRF-2, cells contain-
ing the recombinant viral genome were induced with phorbol
12-myristate-13-acetate (PMA) (30 ng/ml) and butyric acid
(4 μM) for 5 days; supernatant was collected by centrifugation
and filtered through 0.8-μm filters. For each rescue experiment,
1.5–2×106 each of EBV-negative Akata 4E-3 or BJAB cells
were incubated with 1 ml of growth medium containing 0.5,
0.25, or 0.05 ml of the above supernatant for 90 min with gentle
shaking (160 rpm) at 37 °C. Cells were then collected by
centrifugation at 500×g for 5 min and cultured in growth medium
for 36–48 h before the cells were plated into 96-well plates at
104 cells/well. G418-resistant colonies were selected as above.
Real-time DNA PCR and reverse transcription PCR (RT–PCR)
Real-time DNA PCR assays to quantitate total EBV genome
copies were performed using a probe specific for the BZLF-1
gene, as previously described (Xiao et al., 2007). EBV/ΔBMRF-
2 was quantitated using the primers and probe specific for the
neomycin-resistant gene: forward primer, 5′-GCATACGCTT-
GATCCGGCTA; reverse primer, TGATCGACAAGACCGGC-
TTC; probe: CTGCCCATTCGACCACCAAGCG. ForRT–PCR,
the total RNA of each sample was extracted from 4–5×106 cells
using the RNeasy kit (Qiagen, Valencia, CA) according to the
protocols provided by the manufacturer. Reverse transcription
reaction was performed using the iScript reverse transcriptase kitfrom Bio-Rad (Hercules, CA) according to the manufacturer's
protocol. Regular RT–PCR was performed using gene-specific
primers for BZLF-1, BMRF-1, and BMRF-2 and single-stranded
cDNA as templates.
Flow cytometry assays
Expression of BMRF-2 on the cell surface was determined
by flow cytometry using rat anti-BMRF-2 serum (1:50). Cells
were washed once with cold phosphate-buffered saline (PBS)
and incubated with primary antibodies in PBS (pH 7.4) con-
taining 1% bovine serum albumin (BSA) for 1 h on ice. Cells
were then washed three times (5 min each) in PBS by centri-
fugation and reacted with phycoerythrin-labeled goat–anti-rat
antibodies for 30 min at 4 °C. Cells were analyzed in a
fluorescence-activated cell sorting (FACS) cytometer (Becton-
Dickinson and Company, San Jose, CA).
Gradient purification of EBV viruses
Production of EBV was achieved by culturing cells with
PMA (30 ng/ml) and butyric acid (4 μM) (Sigma) for 5 days,
after which virion-containing media were clarified by centrifu-
gation at 500×g for 5 min and filtered through a 0.8-μm mem-
brane. Gradient purification of EBV was performed as
previously described (Xiao et al., 2007). Briefly, virions were
concentrated by centrifugation at 16,000×g for 90 min and
resuspended in Tris–sodium chloride–bacitracin (TNB) buffer
(10 mM Tris–HCl, pH 7.2, 150 mMNaCl, 100 μg/ml bacitracin
[Sigma]). Each aliquot of 0.5 ml of concentrated virions was
then loaded onto 9 ml of 24–42% Histodenz gradient (Sigma)
and centrifuged at 70,000×g for 2 h, and the upper three 0.5-ml
fractions were collected and combined. Purified virions were
then washed in TNB buffer three times using Amicon Ultra-100
centrifugal filter devices (Millipore, Billerica, MA) to remove
Histodenz. The purification process was repeated once for double
gradient purification. Titers of gradient purified EBV were then
determined by real-time DNA PCR as described above.
Western blot assays
The BMRF-1 protein was detected using a Western blot assay
with monoclonal antibody (mAb) to EBV p52/50 (Ea D,
Advanced Biotechnologies, Columbia, MD) and NuPage 10%
Bis–Tris gel (Invitrogen). The BMRF-2 protein was detected
using rat anti-BMRF-2 serum (Tugizov et al., 2003), and gp350/
220 was detected using a mouse monoclonal antibody (ViroStat,
Portland, ME). To detect BMRF-2 and gp350/220 in cells
producing the wild-type (WT) EBV or EBV/ΔBMRF-2, the
membrane fractions of B95-8 (WT) and B27-BMRF-2low (EBV/
ΔBMRF-2) cells were extracted and proteins were separated on
SDS–polyacrylamide gel with 7 M urea, as previously described
(Xiao et al., 2007). Antibody to EBNA-1 was purchased from
Advanced Biotechnologies (Columbia, MD). Anti-β-actin was
obtained fromAmbio (Austin, TX). All secondary antibodieswere
purchased from Jackson ImmunoResearch Laboratories (West
Grove, PA). The protein bands were visualized using the ECL
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pixels (mean density) of protein bands using NIH image software.
Quantitation of released virions
To measure the rate of virion release, B95-8 or B27-BMRF-
2low cells were cultured for 5 days with PMA (30 ng/ml) and
butyric acid (4 μM); cells and culture media were separated by
centrifugation at 500×g for 5 min. Virions in the supernatants
were concentrated by centrifugation at 16,000×g for 90 min.
Cellular and viral genomic DNA were then extracted using
AquaPure genomic DNA kits (Bio-Rad). Copy numbers of the
EBV genome in the cells or media were then quantitated by
real-time DNA PCR as described above.
Virus attachment assay
Virus was propagated by inducing B95-8 or B27-BMRF-
2low cells with 30 ng/ml PMA and 4 μM butyric acid (both from
Sigma) for 5 days. Virus was then concentrated using Amicon
Ultra-100 centrifugal filter devices (Millipore) and viral titer
was determined by quantitative real-time PCR. Virus attach-
ment to cells was measured according to the method described
by Shannon-Lowe et al. (2005) with some modifications. HSC-
3sort and Detroitsort cells were grown into 80% confluence,
dissociated with enzyme-free cell dissociation buffer (Invitro-
gen), and washed once with ice-cold PBS. EBV-negative Akata
4E-3 cells were washed once with ice-cold PBS. About 5×105
cells were incubated with different amounts of EBV virions in
PBS at 4 °C for 60 min on a rotator. Cells were then washed
three times with PBS to remove unbound virions, and genomic
DNA was extracted using AquaPure genomic DNA kits (Bio-
Rad). Virus copy numbers were quantitated by real-time PCR as
described above. Virus binding to cells was also detected by
flow cytometry using the following primary antibodies: mono-
clonal anti-gp250/350 (Virostat, Portland, ME), anti-gHgL
(E1D1) (a gift from Dr. L Hutt-Fletcher at Louisiana State
University Health Sciences Center, Shreveport, LA), and anti-
gp110 (Sykesville, MD). After primary antibody reaction, flow
cytometry analyses were then performed as described above.
EBV infection of polarized oral epithelial cells
Polarization of oral epithelial cells and their infection with
EBVwere as described previously (Tugizov et al., 2003). Briefly,
HSC-3sort tongue, Detroitsort, and primary tongue epithelial cells
were cultured on 24-mm-diameter Costar Transwell filters
(Corning Life Sciences, Corning, NY) to form a polarized
monolayer. PolarizedHSC-3sort tongue (between passages 18 and
22) and Detroitsort pharyngeal (between passages 17 and 20) cells
were infected with cell-free EBVat 1000 multiplicity of infection
(MOI)/cell through their basolateral membranes. Since only 10%
of virions may traverse filter pores, the actual MOI will be about
100 virions/cell (Tugizov et al., 2003). Five days after infection,
cells were fixed with 3% paraformaldehyde in PBS at 4 °C for
30 min and immunostained with mouse monoclonal anti-gp350/
220 antibody and Texas red-labeled goat anti-mouse secondaryantibodies. Cells were analyzed using a krypton–argon laser
coupled with a Bio-RadMRC2400 confocal head (Bio-Rad). The
data were analyzed using Laser Sharp software (Bio-Rad).
Site-directed mutagenesis of the BMRF-2 protein
The extracellular domain containing the RGD motif (BMRF-
2 RGD, amino acids 171 to 218) was previously constructed as
a glutathione-S-transferase (GST)–BMRF-2 RGD fusion pro-
tein. The QuikChange Site-Directed Mutagenesis Kit (Strata-
gene, San Diego, CA) was used to mutate the RGD sequence in
the BMRF-2 RGD peptide using the GST–BMRF-2 RGD
fusion gene as a template and the following HPLC-purified
primers (Invitrogen). Primers for the BMRF-2 RGE mutant are
forward primer 5′-tttctgcgcccggggacaacattcggtggc-3′ and re-
verse primer 5′-gccaccgaatgttgtccccgggcgcagaaa. Primers for
the BMRF-2 AAA mutant are forward primer 5′-cattttctgcgcc-
gccgcagctcattcggtggcatc-3′ and reverse primer 5′-gatgccacc-
gaatgagctgcggcggcgcagaaaatg. Mutant plasmids were created
according to the protocols provided by the manufacturer.
Correct substitutions were confirmed by DNA sequencing.
GST-fusion proteins were propagated in the Escherichia coli
Bl-21 strain (Xiao et al., 2007) and purified using Sepharose-4
beads. BMRF-2 peptides were cleaved by thrombin (Amer-
sham, Piscataway, NJ) according to protocols provided by the
manufacturer. After thrombin cleavage, peptide fragments were
washed three times and concentrated in PBS using Amicon
Ultra-10 centrifugal filter devices (Millipore). Endotoxin
was measured using the Limulus Amebocyte Lysate assay kit
E-TOXATE (Sigma), and the endotoxin level in purified
proteins was less than 0.001 EU/mg.
Cell adhesion assay
Cell adhesion assays were carried out according to published
protocols (Wang et al., 2003) with some modifications. Briefly,
Maxisorp 96-well plates (Nalge Nunc International, Rochester,
NY) were coated with 100 μl of BMRF-2 RGD, BMRF-2 RGE,
BMRF-2 AAA peptide, or fibronectin at different concentrations
overnight at 4 °C in PBS, washed three times with cold PBS, and
incubated with 1% BSA in PBS at 4 °C for 2 h to block
nonspecific protein binding. The plates were then washed three
times with PBS before use. HSC-3sort cells grown to 80%
confluence were dissociated with enzyme-free Cell Dissociation
Buffer (Invitrogen) and washed once with serum-free DMEM.
To determine the role of integrins in cell adhesion, cells were
incubated with rat anti-β1 mAb (AIIB2, Hybridoma Bank, The
University of Iowa, Iowa City, IA) or mouse anti-αvmAb (MAB
2021Z) (Chemicon, Temecula, CA) for 1 h at 4 °C. In parallel
experiments the RGD-coated plates were incubated with rat anti-
BMRF-2 serum, EBV-negative (Blackhawk BioSystem, Inc.,
San Ramon, CA) or EBV-positive (gift from Evelyn Lennette,
Virolab, Berkeley, CA) human serum. Cells were resuspended in
DMEM and added to the protein-coated plates at 2×104 cells/
well in 100 μl DMEM. After 1 h of incubation at 37 °C in a 5%
CO2 incubator, the plates were washed four times with DMEM to
remove unbound cells. Attached cells were then fixed with 4%
441J. Xiao et al. / Virology 370 (2008) 430–442paraformaldehyde, stained with crystal violet, and quantitated by
measuring the absorbance at 595 nm in an enzyme-linked
immunosorbent assay plate-reader (Spectra Max340, Molecular
Devices, Sunnyvale, CA).
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